CD274 and neoplasm: We specifically analyzed tumors that were TIL− to reduce the impact of immune cell signaling on tumor PD-L1 expression, and we divided these tumors into group 1 (PD-L1−, n = 180) and group 2 (PD-L1+, n = 54).